Medical devices, healthcare technology and the business of care
510(k) clearance · K253514

Minnesota Four-Lumen Esophagogastric Tamponade Tube - 18 French (0092220); Blakemore Esophageal-Nasogastric Tube - 20 French (0092100); Blakemore Esophageal-Nasogastric Tube - 16 French (0092300)

C.R. Bard, Inc. · Decision date Jul 10, 2026

FDA DECISIONK253514

What did the FDA decide?

FDA records K253514 as a 510(k) premarket notification, with a decision dated Jul 10, 2026. The decision code SESE records a finding of substantial equivalence. This is a 510(k) clearance.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Gastroenterology, Urology
Decision date
Jul 10, 2026

FDA source record

Regulatory record facts

Identifier
K253514
Regulatory pathway
510(k) premarket notification
Product code
KNT
Decision code
SESE
Decision date
Jul 10, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Tubes, Gastrointestinal (And Accessories).

Product code
KNT
FDA device class
2

FDA decision timeline

  1. K253514 received

    Application receipt date recorded by FDA.

  2. K253514 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code KNT

Product / regulatory recordCompanyPathwayDecision dateSource
Danumed Medizintechnik GmbH510(k) clearanceSep 30, 2026FDA
Boehringer Laboratories, LLC510(k) clearanceAug 14, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

C.R. Bard, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Covington, GA

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records